Mesalamine and Injection site cyst - a phase IV clinical study of FDA data


Injection site cyst is reported only by a few people who take Mesalamine.

The phase IV clinical study analyzes which people take Mesalamine and have Injection site cyst. It is created by eHealthMe based on reports of 14,816 people who have side effects while taking Mesalamine from the FDA, and is updated regularly.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Oct, 04, 2022

14,816 people reported to have side effects when taking Mesalamine.
Among them, 2 people (0.01%) have Injection site cyst.

What is Mesalamine?

Mesalamine has active ingredients of mesalamine. It is often used in ulcerative colitis. eHealthMe is studying from 15,051 Mesalamine users for its effectiveness, alternative drugs and more.

What is Injection site cyst?

Injection site cyst is found to be associated with 173 drugs and 85 conditions by eHealthMe.

Number of Mesalamine and Injection site cyst reports submitted per year:

Could Mesalamine cause Injection site cyst?

Gender of people who have Injection site cyst when taking Mesalamine *:

  • female: 100 %
  • male: 0.0 %

Age of people who have Injection site cyst when taking Mesalamine *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 100 %
  • 50-59: 0.0 %
  • 60+: 0.0 %

Common drugs people take besides Mesalamine *:

  1. Somavert: 2 people, 100.00%
  2. Omeprazole: 2 people, 100.00%
  3. Lorazepam: 2 people, 100.00%
  4. Ibuprofen: 2 people, 100.00%
  5. Ramipril: 1 person, 50.00%
  6. Dexamethasone: 1 person, 50.00%

Common side effects people have besides Injection site cyst *:

  1. Weakness: 2 people, 100.00%
  2. Malaise (a feeling of general discomfort or uneasiness): 2 people, 100.00%
  3. Injection Site Irritation: 2 people, 100.00%
  4. Injection Site Haemorrhage (bleeding from injection site): 2 people, 100.00%
  5. Hyperparathyroidism Primary (an abnormally high concentration of parathyroid hormone in the blood, resulting in weakening of the bones through loss of calcium- primary): 2 people, 100.00%
  6. Fatigue (feeling of tiredness): 2 people, 100.00%
  7. Fat Tissue Increased: 2 people, 100.00%
  8. Drug Administration Error: 2 people, 100.00%
  9. Drowsiness: 2 people, 100.00%
  10. Anaemia (lack of blood): 2 people, 100.00%

Common conditions people have *:

  1. Acromegaly (body produces too much growth hormone, leading to excess growth of body tissues): 2 people, 100.00%

* Approximation only. Some reports may have incomplete information.

Do you take Mesalamine and have Injection site cyst?

Check whether Injection site cyst is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related publications that referenced our studies

Related studies

How severe was Injection site cyst and when was it recovered:

Expand to all the drugs that have ingredients of mesalamine:

Alternative drugs to, pros and cons of Mesalamine:

Common Mesalamine side effects:

Browse all side effects of Mesalamine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Injection site cyst treatments and more:

COVID vaccines that are related to Injection site cyst:

All the drugs that are associated with Injection site cyst:

All the conditions that are associated with Injection site cyst:

How the study uses the data?

The study uses data from the FDA. It is based on mesalamine (the active ingredients of Mesalamine) and Mesalamine (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).


WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: